Back to Search
Start Over
Therapeutic effect of Topical Sirolimus on Facial Angiofibromas in Patients of Tuberous Sclerosis Complex
- Source :
- Perspectives In Medical Research, Vol 12, Iss 1, Pp 45-48 (2024)
- Publication Year :
- 2024
- Publisher :
- Prathima Institute of Medical Sciences, 2024.
-
Abstract
- Introduction: Tuberous sclerosis complex (TSC) is a rare autosomal dominant disorder. Facial angiofibromas are the most common cutaneous findings of TSC. Treatment modalities such as laser, surgery, and/or cryotherapy are employed. Topical therapy with Sirolimus, an mTOR inhibitor, showed beneficial effects. Objective: To study the effects of topical sirolimus (0.1%) on Facial Angiofibromas in patients of TSC. Methodology: Four patients with facial angiofibromas were included. They applied Sirolimus preparation twice daily, for 3 months. The Facial Angiofibroma Severity Index (FASI) was recorded pre-intervention, at 3 months and after 6 months. Results: All the patients showed a reduction in the FASI score at the end of three months of therapy. In three patients, on discontinuing therapy, there was no change in the FASI score at the end of six months, i.e., FASI 3 and FASI 6 were the same. Conclusion: Topical sirolimus is an effective treatment for facial angiofibroma in patients with TSC.
- Subjects :
- facial angiofibroma
topical sirolimus
tuberous sclerosis complex
Medicine
Subjects
Details
- Language :
- English
- ISSN :
- 23481447 and 2348229X
- Volume :
- 12
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Perspectives In Medical Research
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.7a1be79927b46179aaae0fac526c216
- Document Type :
- article
- Full Text :
- https://doi.org/10.47799/pimr.1201.09